Author

Marie-Anne Damiette Smit

Observed names: Damiette Smit, M. Damiette Smit, Marie-Anne D. Smit, Marie-Anne Smit, Marie‐Anne Damiette Smit

Institution: Boulder Language Technologies (United States)

Observed institutions: Aurora Health Care, American Society of Clinical Oncology, United States Food and Drug Administration, Amgen (United States), Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Emory University, Genentech, Johns Hopkins Medicine, Boulder Language Technologies (United States), Janssen (Netherlands)

OpenAlex ID: A5112439857

DLL3: an emerging target in small cell lung cancer

2019 · Dwight H. Owen, Michael J. Giffin, et al. · Journal of Hematology & Oncology · 239

PDF

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group

2017 · Stuart M. Lichtman, R. Donald Harvey, et al. · Journal of Clinical Oncology · 186

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

2020 · Albiruni RA Razak, James M Cleary, et al. · Journal for ImmunoTherapy of Cancer · 123

PDF

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

2023 · Bhagirathbhai R. Dholaria, Katja Weisel, et al. · Journal of Clinical Oncology · 66

PDF

Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

2023 · Di Zhou, Lauren A. Byers, et al. · The Journal of Clinical Pharmacology · 51

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

2023 · Jeffrey Matous, Noa Biran, et al. · Blood · 45

Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).

2019 · Lauren Averett Byers, Alberto Chiappori, et al. · Journal of Clinical Oncology · 34

A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).

2022 · Paula Rodríguez-Otero, Anita D'Souza, et al. · Journal of Clinical Oncology · 31

697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC)

2022 · Lauren Byers, John Heymach, et al. · Regular and Young Investigator Award Abstracts · 27

PDF

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

2025 · Ajai Chari, Niels W. C. J. van de Donk, et al. · Blood · 25

PDF

Cancer Immunoprevention—The Next Frontier

2014 · Marie-Anne D. Smit, Elizabeth M. Jaffee, et al. · Cancer Prevention Research · 22

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

2023 · Larysa Sanchez, Carolina Schinke, et al. · Blood · 18

Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.

2023 · Paula Rodríguez-Otero, Carolina D. Schinke, et al. · Journal of Clinical Oncology · 17

Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).

2019 · Marie-Anne Damiette Smit, Hossein Borghaei, et al. · Journal of Clinical Oncology · 16

S192: Talquetamab (tal) + Daratumumab (dara) in Patients (pts) With Relapsed/refractory Multiple Myeloma (rrmm): Updated Trimm-2 Results

2023 · Nizar J Bahlis, Katja Weisel, et al. · HemaSphere · 9

Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).

2020 · Taofeek Kunle Owonikoko, Hossein Borghaei, et al. · Journal of Clinical Oncology · 9

359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

2020 · Hossein Borghaei, Michael Boyer, et al. · Regular and Young Investigator Award Abstracts · 6

PDF

P892: Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/refractory Multiple Myeloma (rrmm) Treated With Talquetamab (tal) Monotherapy in Monumental-1

2023 · Leo Rasche, Carolina Schinke, et al. · HemaSphere · 4

FDA analysis of grade 3-4 safety events.

2017 · Marie-Anne Damiette Smit, Sandra J. Casak, et al. · Journal of Clinical Oncology · 3

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

2025 · Andreas Hochhaus, Susanne Saussele, et al. · Blood · 2

627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

2020 · Keegan Cooke, Juan Estrada, et al. · Regular and Young Investigator Award Abstracts · 1

Food and Drug Administration analysis of 1332 single patient and emergency use expanded access (compassionate use) requests for patients with cancer over a duration of three years (2012-2014).

2016 · Steven J. Lemery, Sham Mailankody, et al. · Journal of Clinical Oncology · 1

Maintenance therapy in solid tumors

2012 · Marie-Anne Smit, John L. Marshall · Community Oncology

Works count: 23

Citation count: 935

H-index: 14

I10-index: 14